Subject(s)
Neovascularization, Physiologic/physiology , Regeneration/physiology , Stem Cell Transplantation/methods , Vascular Diseases/therapy , Adult Stem Cells/transplantation , Embryonic Stem Cells/transplantation , Humans , Pluripotent Stem Cells/transplantation , Stem Cell Transplantation/trends , Vascular Diseases/physiopathologyABSTRACT
Vascular dysfunction is linked with increased free radical generation and is a major contributor to the high mortality rates observed in diabetes. Several probable sources of free radical generation have been suggested in diabetes, including cytochrome P450 (CYP) monooxygenase-dependent pathways. CYP-mediated superoxide production reduces nitric oxide (NO) bioavailability. In this study, we focus on the contribution of monooxygenase enzyme-generated reactive oxygen species in vascular dysfunction in an experimental model of diabetes mellitus type II. Diabetic male mice (db/db strain) and their age-matched controls received daily intraperitoneal injections of either the CYP 2C inhibitor sulfaphenazole (5.13 mg/kg) or saline (vehicle control) for 8 weeks. Although sulfaphenazole did not change endothelium-dependent vasodilation in control mice, it restored endothelium-mediated relaxation in db/db mice. We report for the first time that CYP 2C inhibition reduces oxidative stress (measured as plasma levels of 8-isoprostane), increases NO bioavailability (measured as NO(2)(-)) and restores endothelial function in db/db mice without affecting plasma glucose levels. Based on our findings, we speculate that inhibition of free radical generating CYP 450 monooxygenase enzymes restores endothelium-dependent vasodilation to acetylcholine. In addition, it reduces oxidative stress and increases NO bioavailability.
Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Endothelium, Vascular/physiopathology , Sulfaphenazole/pharmacology , Vasodilation/drug effects , Acetylcholine/pharmacology , Animals , Antioxidants/pharmacology , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Aorta, Thoracic/physiopathology , Biomarkers/blood , Blood Glucose/analysis , Cyclic N-Oxides/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System , Diabetes Mellitus, Type 2/genetics , Dinoprost/analogs & derivatives , Dinoprost/blood , Dose-Response Relationship, Drug , Fasting/blood , In Vitro Techniques , Injections, Intraperitoneal , Male , Mice , Mice, Mutant Strains , Nitrites/metabolism , Nitroprusside/pharmacology , Spectrophotometry/methods , Spin Labels , Sulfaphenazole/administration & dosage , Vitamin E/pharmacologyABSTRACT
Apoptosis repressor with caspase recruitment domain (ARC), an anti-apoptotic protein, is highly expressed in differentiated heart and skeletal muscle. Apoptosis and differentiation share numerous common pathways; therefore, we examined the impact of ARC on H9c2-myoblast differentiation. We demonstrate that ARC expression levels increase and stabilize upon differentiation. ARC-overexpression in pre-differentiated H9c2-cells suppresses differentiation; indicated by increased myotube formation, nuclear fusion and expression of the differentiation markers myogenin and troponin-T. ARC-overexpression inhibited myoblast differentiation associated caspase-3 activation, suggesting ARC inhibits myogenic differentiation through caspase inhibition. In summary, we show a novel role for ARC in the regulation of muscle differentiation.
Subject(s)
Apoptosis Regulatory Proteins/metabolism , Muscle Proteins/metabolism , Myoblasts, Cardiac/cytology , Myoblasts, Cardiac/metabolism , Animals , Apoptosis Regulatory Proteins/genetics , Caspase 3/metabolism , Cell Differentiation/physiology , Cell Line , Enzyme Activation , Gene Expression , Muscle Development/physiology , Muscle Proteins/genetics , Rats , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , TransfectionABSTRACT
Cytochrome p450 (CYP) inhibitors provide protection against myocardial infarction following both global and focal cardiac ischemia and reperfusion (I/R). We hypothesized that sulfaphenazole, an inhibitor of CYP2C6 and 9, also attenuates post-ischemic endothelial dysfunction by reducing CYP-mediated superoxide generation (which scavenges nitric oxide (NO)), thereby restoring NO bioavailability and vascular tone. Rat hearts were perfused in the Langendorff mode for 20 min in the presence, or absence, of sulfaphenazole and then subjected to 30 min global no-flow ischemia followed by 15 min reperfusion. Septal coronary resistance arteries were isolated and mounted on glass cannulae for measurements of luminal diameter. Preconstricted arteries were exposed to acetylcholine to elicit endothelium-dependent, NO-mediated vasodilation. Acetylcholine caused near maximal dilation in control tissues not subjected to I/R. Following I/R, endothelium-dependent vasodilation was reduced. Pretreatment with sulfaphenazole restored endothelial sensitivity to acetylcholine. Vasoresponsiveness to endothelium-independent vasodilators, sodium nitroprusside and isoproterenol, were also reduced following I/R. However, sensitivity to endothelium-independent vasodilators was not restored by pretreatment with sulfaphenazole. I/R-induced superoxide production was assessed by dihydroethidium staining of flash frozen hearts. Sulfaphenazole treatment significantly reduced superoxide production in arterial walls following I/R injury. We conclude that sulfaphenazole restores post-ischemic endothelium-dependent, NO-mediated vasodilation by reducing superoxide production, suggesting that CYP2C9 plays a key role in post-ischemic vascular dysfunction.
Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Ischemia/complications , Steroid 21-Hydroxylase/antagonists & inhibitors , Vascular Diseases/etiology , Vascular Diseases/prevention & control , Animals , Cytochrome P-450 Enzyme System , Cytochrome P450 Family 2 , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Ethidium/analogs & derivatives , Fluorescent Dyes , Heart/drug effects , In Vitro Techniques , Male , Muscle, Smooth, Vascular/drug effects , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Sulfaphenazole/pharmacologyABSTRACT
The past decade has seen a surge in research devoted to understanding the role of cell death in the pathogenesis of various forms of cardiovascular disease. In particular, apoptosis has received much attention owing to the tightly regulated biochemical nature of this form of cell death and the realization of potential therapeutic opportunities. The current chapter describes a few of the more widely used protocols for detecting and quantifying apoptosis in cardiovascular tissues. Specifically, this chapter describes terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining for DNA fragmentation, Hoechst staining for chromatin condensation, annexin V labeling of phosphatidylserine externalization, and Western blot and immunoflorescence detection of caspase cleavage and activation, respectively.
Subject(s)
Apoptosis , Cardiovascular Diseases/physiopathology , Animals , Annexin A5/metabolism , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Caspases/analysis , Cell Death , Cells, Cultured , DNA Fragmentation , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Humans , In Situ Nick-End Labeling , Mitochondria, Heart/metabolism , Muscle, Smooth, Vascular , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Staining and LabelingABSTRACT
OBJECTIVE: T cell-induced cytotoxicity, of which granzyme B is a key mediator, is believed to contribute to the pathogenesis of inflammatory vascular diseases. In this report, we investigate the mechanism of granzyme B-induced smooth muscle cell (SMC) death. METHODS AND RESULTS: The addition of purified granzyme B alone to cultured SMCs caused a significant reduction in cell viability. Chromatin condensation, phosphatidylserine externalization, and membrane blebbing were observed, indicating that the mechanism of granzyme B-induced SMC death was through apoptosis. Activated splenocytes from perforin-knockout mice induced SMC death through a granzyme B-mediated pathway. Inhibition of the proteolytic activities of caspases and granzyme B prevented granzyme B-induced SMC death, whereas attenuation of granzyme B internalization with mannose-6-phosphate (M6P) did not. Further, granzyme B induced the cleavage of several SMC extracellular proteins, including fibronectin, and reduced focal adhesion kinase phosphorylation. CONCLUSIONS: These results indicate that granzyme B can induce apoptosis of SMCs in the absence of perforin by cleaving extracellular proteins, such as fibronectin.
Subject(s)
Apoptosis/physiology , Extracellular Matrix/metabolism , Membrane Glycoproteins/deficiency , Myocytes, Smooth Muscle/physiology , Serine Endopeptidases/physiology , Animals , Caspase 3 , Caspases/metabolism , Cell Line, Tumor , Cell Survival/physiology , Coronary Vessels/enzymology , Coronary Vessels/metabolism , Extracellular Matrix/enzymology , Extracellular Matrix Proteins/metabolism , Granzymes , HeLa Cells/chemistry , HeLa Cells/metabolism , Humans , Membrane Glycoproteins/physiology , Mice , Mice, Inbred C57BL , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/physiology , Myocytes, Smooth Muscle/enzymology , Perforin , Pore Forming Cytotoxic Proteins , Rats , Serine Endopeptidases/metabolism , Spleen/cytology , Spleen/metabolismABSTRACT
The cytochrome p450 (CYP) superfamily is responsible for the oxidation, peroxidation, and (or) reduction of vitamins, steroids, xenobiotics, and the majority of cardiovascular drugs in an oxygen- and NADPH-dependent manner. Although hepatic CYP have been studied extensively, the role of CYP in cardiovascular physiology and disease is poorly understood. Increasing evidence suggests that these enzymes play an important role in the pathogenesis of a number of cardiovascular diseases. The current review summarizes the understanding as to the role that dysregulated CYP expression and (or) activity may play in the onset and progression of cardiovascular disease.
Subject(s)
Cardiovascular Diseases/enzymology , Cytochrome P-450 Enzyme System/physiology , Animals , Homeostasis/physiology , Humans , Neovascularization, Pathologic/physiopathologyABSTRACT
Increasingly complex bioinformatic analysis is necessitated by the plethora of sequence information currently available. A total of 21 poxvirus genomes have now been completely sequenced and annotated, and many more genomes will be available in the next few years. First, we describe the creation of a database of continuously corrected and updated genome sequences and an easy-to-use and extremely powerful suite of software tools for the analysis of genomes, genes, and proteins. These tools are available free to all researchers and, in most cases, alleviate the need for using multiple Internet sites for analysis. Further, we describe the use of these programs to identify conserved families of genes (poxvirus orthologous clusters) and have named the software suite POCs, which is available at www.poxvirus.org. Using POCs, we have identified a set of 49 absolutely conserved gene families-those which are conserved between the highly diverged families of insect-infecting entomopoxviruses and vertebrate-infecting chordopoxviruses. An additional set of 41 gene families conserved in chordopoxviruses was also identified. Thus, 90 genes are completely conserved in chordopoxviruses and comprise the minimum essential genome, and these will make excellent drug, antibody, vaccine, and detection targets. Finally, we describe the use of these tools to identify necessary annotation and sequencing updates in poxvirus genomes. For example, using POCs, we identified 19 genes that were widely conserved in poxviruses but missing from the vaccinia virus strain Tian Tan 1998 GenBank file. We have reannotated and resequenced fragments of this genome and verified that these genes are conserved in Tian Tan. The results for poxvirus genes and genomes are discussed in light of evolutionary processes.